Pharmaceuticals News and Research

RSS

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

Celtic Pharmaceutical Holdings L.P., the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also known as a fungal nail infection).

30 Apr 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

ISTA Pharmaceuticals, Inc., today reported financial results for the quarter ended March 31, 2010. First quarter 2010 net revenues were $28.3 million, an increase of 39% from the first quarter of 2009. Net income for the first quarter ended March 31, 2010, was $0.5 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.59 per share, for the first quarter ended March 31, 2009.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

UNICEF, WHO release new publication on medicines formulated for children

A new publication that lists medicines formulated for children is being made available online by UNICEF and the World Health Organization, to help doctors and organizations obtain some of the 240 essential medicines that can save the lives of children.

30 Apr 2010

Practicing NPIs may help limit transmission of pandemic flu: Study

Practicing non-pharmaceutical interventions such as hand-washing and mouth covering may help limit the transmission of the pandemic flu, but more research on these measures is critical according to a new study appearing in the May issue of AJIC: American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology, Inc.

30 Apr 2010

Public health officials lay out opportunities, challenges related patient care at USP 2010 Membership Meeting

Four of the nation's leading public health officials laid out opportunities and challenges in the diverse area of patient care in the 21st century at the recently concluded U.S. Pharmacopeial Convention's 2010 Membership Meeting in Washington, D.C., emphasizing the critical nature of partnerships and the evolving role of quality standards to meet modern threats.

30 Apr 2010

SeraCare reports 18% increase in second-quarter fiscal 2010 revenues

SeraCare Life Sciences, Inc., a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today reported operational and financial results for its second quarter of fiscal year 2010, ended March 31, 2010.

30 Apr 2010

FDA critics say controversy about diabetes drug points to need for agency changes

Reuters: "The controversy surrounding a GlaxoSmithKline Plc diabetes drug points to a need for changes in the way the U.S. Food and Drug Administration handles safety issues, agency critics told lawmakers on Wednesday.

30 Apr 2010

Johnson & Johnson subsidiaries agree to pay over $81M to resolve Topamax illegal promotion allegations

American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, have agreed to pay more than $81 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Topamax, the Justice Department announced today.

30 Apr 2010

Lotus Pharmaceuticals receives Chinese SFDA approval to commence Laevo-Bambuterol clinical trials

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China today reported that its innovative asthma drug Laevo-Bambuterol has received approval from China's State Food & Drug Administration's (SFDA) to commence clinical trials (No.2010L01309 and 2010L01399).

30 Apr 2010

Mylan first-quarter total revenues increase 7% to $1.29 billion

Mylan Inc. today announced its financial results for the three months ended March 31, 2010.

30 Apr 2010

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

Impax Laboratories, Inc. today confirms that it has initiated a challenge of a patent listed by Shionogi Pharma, Inc. in connection with its Fenoglide® (fenofibrate) tablets, 40 and 120 mg.

30 Apr 2010

West Pharmaceutical Services reports 13.3% increase in first-quarter consolidated sales

West Pharmaceutical Services, Inc. today announced its results for the first quarter of 2010.

30 Apr 2010

Clarient reports 14.8% increase in first quarter 2010 revenue

Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the first quarter ended March 31, 2010.

30 Apr 2010

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.

30 Apr 2010

Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis patients with DIC

Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.

30 Apr 2010

Idenix Pharmaceuticals prices underwritten offering of common stock at $4.35 per share

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten offering of 6,460,672 shares of its common stock at a price of $4.35 per share. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $26.2 million. All of the shares are being sold by Idenix.

29 Apr 2010

Investment report on Somaxon Pharmaceuticals from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

29 Apr 2010

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Labopharm Inc. and Gruppo Angelini today announced they have entered into an agreement to establish a joint venture in the United States for the commercialization of OLEPTRO, a novel once-daily formulation of the antidepressant trazodone approved by the U.S. Food and Drug Administration on February 3, 2010.

29 Apr 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

29 Apr 2010

Pharmaceuticals News and Research

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

ISTA Pharmaceuticals first-quarter net revenues up 39%

REGN reports net loss of $30.5M for first-quarter 2010

UNICEF, WHO release new publication on medicines formulated for children

Practicing NPIs may help limit transmission of pandemic flu: Study

Public health officials lay out opportunities, challenges related patient care at USP 2010 Membership Meeting

SeraCare reports 18% increase in second-quarter fiscal 2010 revenues

FDA critics say controversy about diabetes drug points to need for agency changes

Johnson & Johnson subsidiaries agree to pay over $81M to resolve Topamax illegal promotion allegations

Lotus Pharmaceuticals receives Chinese SFDA approval to commence Laevo-Bambuterol clinical trials

Mylan first-quarter total revenues increase 7% to $1.29 billion

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

West Pharmaceutical Services reports 13.3% increase in first-quarter consolidated sales

Clarient reports 14.8% increase in first quarter 2010 revenue

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis patients with DIC

Idenix Pharmaceuticals prices underwritten offering of common stock at $4.35 per share

Investment report on Somaxon Pharmaceuticals from MicroStockProfit.com

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence